Vertex Pharmaceuticals Inc Revenue Growth Rates (VRTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vertex Pharmaceuticals Inc  (NASDAQ: VRTX)
 

VRTX's Revenue Growth by Quarter and Year

Vertex Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRTX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 3,333.90
1st Quarter March 2,986.90
FY 6,320.80

VRTXs Annual Revenue
Vertex Pharmaceuticals Inc's Revenue in the fiscal year 2025 $ 12,001.30 millions
Vertex Pharmaceuticals Inc's Revenue in the fiscal year 2024 $ 11,020.10 millions
Vertex Pharmaceuticals Inc's Revenue in the fiscal year 2023 $ 9,869.20 millions
Vertex Pharmaceuticals Inc's Revenue in the fiscal year 2022 $ 8,930.70 millions
Vertex Pharmaceuticals Inc's Revenue in the fiscal year 2021 $ 7,574.40 millions




VRTX Revenue second quarter 2026 Y/Y Growth Comment
Vertex Pharmaceuticals Inc reported Revenue increase of 12.45% year on year in the second quarter 2026, to $ 3,333.90 millions, this is lower than Vertex Pharmaceuticals Inc's recent average Revenue improvement of 27.47%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue growth. While Vertex Pharmaceuticals Inc' s Revenue growth of 12.45% ranks overall at the positon no. 2398 in the second quarter 2026.


VRTX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 9.55 % 15.66 % 9.34 %
3rd Quarter September - 10.99 % 11.61 % 6.39 %
2nd Quarter June 12.45 % 12.06 % 6.11 % 13.52 %
1st Quarter March 7.82 % 2.96 % 13.3 % 13.22 %
FY   - 8.9 % 11.66 % -

Financial Statements
Vertex Pharmaceuticals Inc's second quarter 2026 Revenue $ 3,333.90 millions VRTX's Income Statement
Vertex Pharmaceuticals Inc's second quarter 2025 Revenue $ 2,964.70 millions Quarterly VRTX's Income Statement


VRTX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 3.69 % 5.05 % 1.38 %
3rd Quarter September - 3.77 % 4.77 % -0.39 %
2nd Quarter June 11.62 % 7.02 % -1.67 % 4.99 %
1st Quarter March -6.37 % -4.87 % 6.87 % 3.13 %
FY (Year on Year)   - 8.9 % 11.66 % -


Back to VRTX Growth rate Comparisons >> Back to VRTX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #351
Overall #2398

Revenue Y/Y Growth Statistics
High Average Low
147.95 % 27.47 % -67.04 %
(June 30. 2016)   (Sep. 30, 2014)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #351
Overall #2398
Revenue Y/Y Growth Statistics
High Average Low
147.95 % 27.47 % -67.04 %
(June 30. 2016)   (Sep. 30, 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Vertex Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
476.1 % 15.17 % -66.27 %
(Sep 30 2011)  


VRTX's II. Quarter Q/Q Revenue Comment
Vertex Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 11.62% quarter on quarter, to $ 3,333.90 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 7.02% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue quarter on quarter growth. While Vertex Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 743.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #120
Overall #743
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #120
Overall #743
Revenue Q/Q Growth Statistics
High Average Low
476.1 % 15.17 % -66.27 %
(Sep 30 2011)  


VRTX's II. Quarter Q/Q Revenue Comment
Vertex Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 11.62% quarter on quarter, to $ 3,333.90 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.02% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue quarter on quarter growth. While Vertex Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 743.


Vertex Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 12,587.20 $ 12,218.00 $ 12,001.30 $ 11,723.30 $ 11,418.80
Y / Y Revenue Growth (TTM) 10.23 % 10.08 % 8.9 % 10.33 % 10.46 %
Year on Year Revenue Growth Overall Ranking # 1455 # 887 # 833 # 1178 # 1076
Seqeuential Revenue Change (TTM) 3.02 % 1.81 % 2.37 % 2.67 % 2.87 %
Seq. Revenue Growth (TTM) Overall Ranking # 2328 # 2391 # 1812 # 1920 # 1945


Cumulative Revenue growth Comment
Although Vertex Pharmaceuticals Inc's Annual Revenue growth year on year were below company's average 72.9% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.23% year on year, from 10.08% in Mar 31 2026.

In the Healthcare sector 244 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 887 to 1455.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 245
Overall # 1455

Revenue TTM Y/Y Growth Statistics
High Average Low
883.91 %
 72.9 %
-52.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 335
S&P 500 # 2328
Cumulative Revenue growth Comment
Although Vertex Pharmaceuticals Inc's Annual Revenue growth year on year were below company's average 72.9% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.23% year on year, from 10.08% in Mar 31 2026.

In the Healthcare sector 244 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 887 to 1455.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 245
Overall # 1455

Revenue TTM Y/Y Growth Statistics
High Average Low
883.91 %
72.9 %
-52.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 335
S&P 500 # 2328




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VRTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
X4 Pharmaceuticals Inc21.64%$ 21.642 millions
Exagen Inc 21.63%$ 21.629 millions
Adaptive Biotechnologies Corporation21.53%$ 21.526 millions
Privia Health Group Inc 21.39%$ 21.390 millions
Bionano Genomics Inc 21.36%$ 21.357 millions
Evolus Inc 21.30%$ 21.298 millions
Invivyd Inc 21.20%$ 21.203 millions
Transmedics Group Inc 20.70%$ 20.702 millions
Irhythm Holdings Inc 20.62%$ 20.615 millions
Delcath Systems Inc 20.60%$ 20.604 millions
Castle Biosciences Inc 20.14%$ 20.140 millions
Procept Biorobotics Corporation20.00%$ 20.004 millions
Biomarin Pharmaceutical Inc19.91%$ 19.905 millions
Cannapharmarx Inc 19.26%$ 19.261 millions
Anika Therapeutics Inc 19.18%$ 19.176 millions
Bioaffinity Technologies Inc 18.99%$ 18.992 millions
Aurinia Pharmaceuticals Inc 18.87%$ 18.872 millions
Camp4 Therapeutics Corporation18.84%$ 18.838 millions
Lensar Inc 18.37%$ 18.371 millions
Immunocore Holdings Plc18.34%$ 18.336 millions
Innovage Holding Corp 18.31%$ 18.307 millions
Koru Medical Systems Inc 18.15%$ 18.153 millions
Clearpoint Neuro Inc 18.07%$ 18.068 millions
Avita Medical Inc 17.83%$ 17.830 millions
Xencor Inc17.46%$ 17.458 millions
Logicmark Inc17.39%$ 17.387 millions
Ensign Group Inc17.33%$ 17.325 millions
Medpace Holdings Inc 17.24%$ 17.242 millions
Geron Corporation17.22%$ 17.220 millions
Si bone inc 17.16%$ 17.159 millions


About Vertex Pharmaceuticals Inc Revenue Growth Rates (VRTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vertex Pharmaceuticals Inc Ma (CIK 875320).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000875320-26-000259
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vertex Pharmaceuticals Inc Ma’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.